Kepler Capital Markets set a €104.00 ($128.40) price objective on Bayer (FRA:BAYN) in a research note published on Friday. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other brokerages also recently issued reports on BAYN. Independent Research set a €102.00 ($125.93) price objective on shares of Bayer and gave the stock a neutral rating in a research note on Thursday, March 1st. equinet set a €118.00 ($145.68) price objective on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, February 28th. Barclays set a €95.00 ($117.28) price objective on shares of Bayer and gave the stock a sell rating in a research note on Monday, March 12th. JPMorgan Chase & Co. reissued a buy rating and issued a price objective on shares of Bayer in a research note on Wednesday, February 28th. Finally, Berenberg Bank set a €124.00 ($153.09) target price on shares of Bayer and gave the stock a neutral rating in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of €119.14 ($147.08).
Shares of Bayer (FRA:BAYN) traded down €0.49 ($0.60) during midday trading on Friday, reaching €95.54 ($117.95). 7,692,945 shares of the company’s stock traded hands. The company has a market capitalization of $78,800.00 and a P/E ratio of 25.68. Bayer has a twelve month low of €91.58 ($113.06) and a twelve month high of €123.82 ($152.86).
COPYRIGHT VIOLATION NOTICE: “Bayer (BAYN) Given a €104.00 Price Target by Kepler Capital Markets Analysts” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://transcriptdaily.com/2018/03/17/bayer-bayn-given-a-104-00-price-target-by-kepler-capital-markets-analysts.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.